In Latvia, the Endocrinologists Association and the Latvian Rural Family Doctors Association have addressed concerns regarding improper prescriptions of the diabetes medication 'Ozempic.' They emphasize that despite some cases of misuse, this medication is critical for treating Type 2 diabetes, assisting in blood glucose control, metabolic improvement, and offering additional cardiovascular and renal protection. The associations warned against generalizing these incidents to undermine the overall practice of diabetes treatment in the country.

President Ainis Dzalbs of the Rural Family Doctors Association highlighted the importance of addressing and investigating any irregular prescriptions without restricting access to this vital treatment. He noted that the group of GLP-1 receptor agonists, which includes 'Ozempic,' is one of the most significant classes of medication for contemporary Type 2 diabetes therapy. Such medications are crucial for managing diabetes and supporting the health of patients in Latvia.

Furthermore, the statements from the medical associations aim to clarify the role of 'Ozempic' and similar medications in the healthcare system, assuring that while oversight should be implemented to prevent misuse, the essential benefits of these drugs for diabetes management should not be overlooked. They call for a balanced approach, ensuring that regulatory actions do not negatively impact patients who genuinely need this treatment.